Vinblastine 10mg/10ml solution for injection vials
Requires a prescription from a doctor or prescriber
Antitumor alkaloid isolated from Vinca rosea.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Vinblastine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Vinblastine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Vinblastine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Vinblastine on the MHRA register
Vinblastine 10mg/10ml solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)
Bladder cancer: diagnosis and management (NG2)
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (TA1097)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 2 · 1975–2026
Showing the 50 most relevant studies, sorted by most relevant.
Hayato Ishikawa, David A. Colby, Dale L. Boger
Journal of the American Chemical Society, 2007
Suresh V. Ambudkar, Carol O. Cardarelli, Irina Pashinsky, et al.
Journal of Biological Chemistry, 1997
C. l. Maignan
Blood, 2004
Barzani HAH, Omer RA, Barzani KIS, et al.
2026
- Neoplasms
- Vinblastine
- Vincristine
Čančarević-Đajić B, Antonić Z, Božić S, et al.
2026
Hodgkin lymphoma during pregnancy is rare and may present diagnostic and therapeutic challenges, particularly when complicated by superior vena cava syndrome, a life-threatening condition. We report a 41-year-old pregnant patient at 30 weeks of gestation who presented with rapidly progressive dyspnea, cervical venous congestion, and facial edema. Imaging revealed a bulky mediastinal mass compressing the superior vena cava. Due to acute maternal risk, an emergency multidisciplinary decision was made to perform cesarean delivery followed by immediate uniportal video-assisted thoracoscopic biopsy. Histopathology confirmed classical Hodgkin lymphoma, nodular sclerosis subtype. Postpartum positron emission tomography/computed tomography demonstrated extensive supradiaphragmatic disease, and chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine was promptly initiated. The patient showed a favorable clinical and metabolic response, and the neonate demonstrated normal early postnatal development. This case highlights the importance of early recognition and multidisciplinary management of superior vena cava syndrome in pregnancy and raises the hypothesis that pregnancy-associated immunologic changes, including interleukin-6-mediated pathways, may contribute to accelerated disease progression.
Abstract licence: CC BY
Tard SC, Shrivastav A, Tanwar GS, et al.
2025
Multisystem Langerhans cell histiocytosis (MS-LCH) is exceedingly rare in very young children and can present with predominant lung involvement. We report a 2-year-old boy who presented with prolonged fever, cough, and acute respiratory distress. Chest imaging revealed recurrent bilateral pneumothoraces requiring multiple chest drains; high-resolution computed tomography showed diffuse bilateral thin-walled lung cysts. Thoracoscopic lung biopsy with immunohistochemistry (CD1a+, CD45+, S100+) confirmed Langerhans cell histiocytosis. Given the strong association between pediatric pulmonary LCH and multisystem disease, a whole-body FDG-PET/CT was performed, revealing hepatic and splenic involvement and confirming a diagnosis of MS-LCH. Systemic chemotherapy with vinblastine and corticosteroids led to clinical improvement. We also review nine similar pediatric cases reported in the literature, highlighting the importance of recognizing pulmonary findings as a gateway to diagnosing underlying multisystem LCH.
Abstract licence: CC BY
- -
http://isrctn.org/>, 2013
Leslie Wilson, Karen M. Creswell, Daniel Chin
Biochemistry, 1975
Winegar PH, Astolfi MC, Holm SF, et al.
2025
- Terpenes
- Metabolic Engineering
- Escherichia coli
Terpenoid natural products and their derivatives exhibit bioactivity that is utilized in FDA-approved drugs and candidates for future drugs; however, the widespread utilization of terpenoids has been limited by complex, low-yielding native biosyntheses and chemical syntheses. Microbial total/semi-biosynthesis of natural and new-to-nature terpenoids from sustainable feedstocks is scalable and can achieve economically viable cost targets. Herein, this review describes foundational advances in synthetic biology and metabolic engineering as exemplified by efforts to biosynthesize prominent terpenoids (i.e. artemisinin, taxol, vinblastine, QS-21, and cyclopamine) in engineered microorganisms (e.g. Escherichia coli and Saccharomyces cerevisiae). Emerging methods that accelerate microbial biosynthesis campaigns (i.e. automation, machine learning, artificial intelligence, and combinatorial screening) are then discussed.
Abstract licence: CC BY
Yousefi F, Mashhadi AA, Lotfi Jalal Abadi A, et al.
2025
- Catharanthus
- Secologanin Tryptamine Alkaloids
- Tryptophan
The leaves of the medicinal-ornamental plant Catharanthus roseus serve as the exclusive source of the anticancer alkaloids vinblastine and vincristine. The limited synthesis of these alkaloids, alongside efforts to enhance their production, has consistently been a focal point of research. Water scarcity, recognized as one of the most significant constraints in agriculture, has prompted this study to examine the effects of the amino acid elicitor tryptophan and drought stress on the alterations in secondary metabolites of C. roseus and the genes implicated in their biosynthetic pathways. This investigation was factorial experiment conducted within a completely randomized design (CRD) with three replications. The first factor involved drought stress (40% and 100% field capacity), the second factor pertained to tryptophan concentrations (0 and 250 ppm), and the third factor encompassed duration (24, 48, 72, and 168 hours). Key genes associated with four metabolic pathways, phenolic/flavonoid, indole, terpenoid, and alkaloid pathways, were analyzed using quantitative polymerase chain reaction (qRT- PCR). Notably, the Cm gene (phenolic/flavonoid pathway) exhibited increased expression across all treatments, with the highest expression level recorded at 168 hours under the combined conditions of tryptophan and drought. Genes associated with the indole alkaloid pathway (As and Tdc) demonstrated similar temporal variations, with peak expression levels observed at 24 hours, particularly under drought stress. Genes within the terpenoid pathway (Sls) and alkaloid pathway (Str, Dat, Prx) displayed an initial increase in expression at 24 hours, followed by a decline at 48 and 72 hours, and a subsequent increase at 168 hours post-treatment in comparison to the control. Additionally, alkaloid accumulation (vincristine, vinblastine) significantly increased, especially under severe drought stress, correlating with the observed gene expression patterns. Non-enzymatic antioxidants, including phenols and flavonoids, also exhibited elevated levels in response to stress and tryptophan treatment. Furthermore, tryptophan application resulted in a doubling of plant biomass compared to the control. Collectively, the findings of this study suggest that the combination of drought stress and tryptophan application modulates gene expression and metabolite production in C. roseus, which may be crucial for optimizing alkaloid biosynthesis under drought stress conditions.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
35 min
Mechanism
The antitumor activity of vinblastine is thought to be due primarily to inhibiti…
Food interactions
2 warnings
Human targets
7 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
35 min
Protein binding
98-99%
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1334 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:38305685 PMID:38609661 PMID:39321809
Gamma-tubulin is a key component of the gamma-tubulin ring complex (gTuRC) which mediates microtubule nucleation .
PMID:38305685 PMID:38609661 PMID:39321809
The gTuRC regulates the minus-end nucleation of alpha-beta tubulin heterodimers that grow into microtubule protafilaments, a critical step in centrosome duplication and spindle formation PMID:38305685 PMID:38609661 PMID:39321809
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
PMID:10064732 PMID:11114332 PMID:16230346 PMID:7961706 PMID:9281595
Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics .
PMID:10064732 PMID:11114332 PMID:16230346 PMID:7961706 PMID:9281595
Confers resistance to anticancer drugs by decreasing accumulation of drug in cells, and by mediating ATP- and GSH-dependent drug export .
PMID:9281595
Hydrolyzes ATP with low efficiency .
PMID:16230346
Catalyzes the export of sphingosine 1-phosphate from mast cells independently of their degranulation .
PMID:17050692
Participates in inflammatory response by allowing export of leukotriene C4 from leukotriene C4-synthesizing cells (By similarity). Mediates ATP-dependent, GSH-independent cyclic GMP-AMP (cGAMP) export .
PMID:36070769
Thus, by limiting intracellular cGAMP concentrations negatively regulates the cGAS-STING pathway .
PMID:36070769
Exports S-geranylgeranyl-glutathione (GGG) in lymphoid cells and stromal compartments of lymphoid organs. ABCC1 (via extracellular transport) with GGT5 (via GGG catabolism) establish GGG gradients within lymphoid tissues to position P2RY8-positive lymphocytes at germinal centers in lymphoid follicles and restrict their chemotactic transmigration from blood vessels to the bone marrow parenchyma (By similarity).
Mediates basolateral export of GSH-conjugated R- and S-prostaglandin A2 diastereomers in polarized epithelial cells PMID:9426231
PMID:10220572 PMID:10421658 PMID:11500505 PMID:16332456
Mediates hepatobiliary excretion of mono- and bis-glucuronidated bilirubin molecules and therefore play an important role in bilirubin detoxification .
PMID:10421658
Also mediates hepatobiliary excretion of others glucuronide conjugates such as 17beta-estradiol 17-glucosiduronic acid and leukotriene C4 .
PMID:11500505
Transports sulfated bile salt such as taurolithocholate sulfate .
PMID:16332456
Transports various anticancer drugs, such as anthracycline, vinca alkaloid and methotrexate and HIV-drugs such as protease inhibitors .
PMID:10220572 PMID:11500505 PMID:12441801
Confers resistance to several anti-cancer drugs including cisplatin, doxorubicin, epirubicin, methotrexate, etoposide and vincristine PMID:10220572 PMID:11500505
PMID:11880368 PMID:12414644
May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Does not appear to actively transport drugs outside the cell.
Confers low levels of cellular resistance to etoposide, teniposide, anthracyclines and cisplatin PMID:12414644
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132
Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269
PMID:10358072 PMID:15159445 PMID:17412826
Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-thyronine) .
PMID:10358072 PMID:10601278 PMID:10873595 PMID:11159893 PMID:12196548 PMID:12568656 PMID:15159445 PMID:15970799 PMID:16627748 PMID:17412826 PMID:19129463 PMID:26979622
Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop .
PMID:22232210
Involved in the clearance of endogenous and exogenous substrates from the liver .
PMID:10358072 PMID:10601278
Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition .
PMID:26383540
May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins), such as pravastatin and pitavastatin, a clinically important class of hypolipidemic drugs .
PMID:10601278 PMID:15159445 PMID:15970799
May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drug methotrexate .
PMID:23243220
May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver .
PMID:16624871 PMID:16627748
Shows a pH-sensitive substrate specificity towards prostaglandin E2 and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment .
PMID:19129463
Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions PMID:19129463
Involved compounds
ATC L01CA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Vinblastine
Additional database identifiers
Drugs Product Database (DPD)
9407
ChemSpider
12773
BindingDB
50012278
PDB
VLB
ZINC
ZINC000085432544
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20766
GenAtlas
TUBA1A
GeneCards
TUBA1A
GenBank Gene Database
X01703
GenBank Protein Database
37492
UniProt Accession
TBA1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20778
GenAtlas
TUBB
GeneCards
TUBB
GenBank Gene Database
J00314
GenBank Protein Database
338695
Guide to Pharmacology
2640
UniProt Accession
TBB5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:16811
GeneCards
TUBD1
GenBank Gene Database
AF201333
GenBank Protein Database
6457580
UniProt Accession
TBD_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12417
GeneCards
TUBG1
GenBank Gene Database
M61764
GenBank Protein Database
183703
UniProt Accession
TBG1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20775
GeneCards
TUBE1
GenBank Gene Database
AF201334
GenBank Protein Database
6457582
UniProt Accession
TBE_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12412
GenAtlas
TUBB2A
GeneCards
TUBB2A
GenBank Gene Database
X79535
UniProt Accession
TBB2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6204
GenAtlas
JUN
GeneCards
JUN
GenBank Gene Database
J04111
GenBank Protein Database
386839
UniProt Accession
JUN_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:51
GenAtlas
ABCC1
GeneCards
ABCC1
GenBank Gene Database
L05628
GenBank Protein Database
1835659
Guide to Pharmacology
779
UniProt Accession
MRP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:53
GenAtlas
ABCC2
GeneCards
ABCC2
GenBank Gene Database
U63970
GenBank Protein Database
1764162
Guide to Pharmacology
780
UniProt Accession
MRP2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:57
GeneCards
ABCC6
GenBank Gene Database
AF076622
GenBank Protein Database
3928849
UniProt Accession
MRP6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:42
GenAtlas
ABCB11
GeneCards
ABCB11
GenBank Gene Database
AF091582
GenBank Protein Database
3873243
Guide to Pharmacology
778
UniProt Accession
ABCBB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10959
GenAtlas
SLCO1B1
GeneCards
SLCO1B1
GenBank Gene Database
AF060500
GenBank Protein Database
5051630
Guide to Pharmacology
1220
UniProt Accession
SO1B1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72